Nephrolyx GmbH, a German company, has developed an innovative tool for measuring GFR in clinical routine. The Nephrolyx IVDx combines an IVD kit with a digital platform and is ready-to-use.
Applying Iohexol-Plasma-Clearance method, this test delivers results within just a few hours. It empowers physicians to precisely detect renal diseases and to adjust treatment plans for patients right on time.
Nephrolyx IVDx is recommended for clinical, analytical, and research laboratory settings that use semi-automatic processing in a UHPLC or HPLC device.
The test is not only suitable for both acute and non-acute patient scenarios but also highly adaptable to various clinical situations.
Precise
Nephrolyx IVDx offers superior precision and accuracy in results compared to GFR estimates. Additionally, the test consistently performs accurately in all situations across the GFR range, enabling the early detection of changes in GFR. Moreover, it is not affected by non-GFR determinants.
Affordable
Nephrolyx IVDx stands out as a cost-effective option when compared to other mGFR solutions, including Creatinine-Clearance, 99mTc-DTPA, lab-developed mGFR tests (LDTs), and even several biomarker-based estimates (eGFR).
Rapid
Nephrolyx IVDx provides clinical results within the same day, with a turnaround time of less than 6 hours, which is significantly quicker than LDTs for mGFR.
Obtaining diagnostic results more quickly accelerates and simplifies sample processing.